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INTRODUCTION
Prostate cancer (CaP) is one of the most common malignancies 
in Western males, and the prevalence of CaP in Korean men is 
increasing [1,2]. Prostate infection and inflammation caused by 
bacteria and viruses are thought to be important drivers of car-
cinogenesis in CaP [3-5]. A meta-analysis investigating the re-
lationship between sexually transmitted diseases (STDs) and 
the risk for CaP suggested that men with a history of infection 
with any STD or gonorrhea, specifically, exhibited increased 
risks of CaP (1.5 fold and 1.2 fold, respectively) [6]. However, 
the existence of a causal relation between inflammation from 
infection and prostate carcinogenesis is still debatable [3]. Sev-
eral studies have suggested that viral microRNAs (miRNAs), 
mostly derived from herpes viruses, facilitate cross-talk be-
tween the virus and host during viral infection and pathogene-
sis [7,8]. For instance, viral miRNAs acting directly as onco-
genes can be illustrated by the Kaposi’s sarcoma-associated her-
pesvirus miR-K12-10 and miR-K12-12, both encoded within 
the transcript of the A isoform of kaposin, which is known to 
mediate cellular transformation through loss of growth control 
and cell surface-mediated inhibition [9]. Thus, a causal associa-
tion between viral miRNAs and carcinogenesis should not be 
dismissed, even though evidence is limited. 
 Recently, we reported the presence of virus-encoded miR-
NAs in the urine of patients with CaP as a marker to distinguish 
between cancer and noncancerous benign prostatic hyperplasia 
(BPH) [10]. Urinary hsv2-miR-H9-5p proved to be a better di-
agnostic than serum prostate-specific antigen (PSA) in the in-
determinate “gray zone,” and it was comparable to serum PSA 
in patients with CaP who underwent transrectal biopsy. The 
combination of miRNA and serum PSA measurements, there-
fore, may prevent unnecessary biopsy, making miRNA a clini-
cally valuable diagnostic marker. To further this line of inquiry 
and potentially identify an additional marker of CaP, the ex-
pression of two viral miRNAs, hsv1-miR-H18 and hsv2-miR-
Purpose: Previously, we reported the presence of virus-encoded microRNAs (miRNAs) in the urine of prostate cancer (CaP) 
patients. In this study, we investigated the expression of two herpes virus-encoded miRNAs in prostate tissue. 
Methods: A total of 175 tissue samples from noncancerous benign prostatic hyperplasia (BPH), 248 tissue samples from pa-
tients with CaP and BPH, and 50 samples from noncancerous surrounding tissues from these same patients were analyzed for 
the expression of two herpes virus-encoded miRNAs by real-time polymerase chain reaction (PCR) and immunocytochemis-
try using nanoparticles as molecular beacons. 
Results: Real-time reverse transcription-PCR results revealed significantly higher expression of hsv1-miR-H18 and hsv2-miR-
H9-5p in surrounding noncancerous and CaP tissues than that in BPH tissue (each comparison, P<0.001). Of note, these 
miRNA were expressed equivalently in the CaP tissues and surrounding noncancerous tissues. Moreover, immunocytochem-
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herpes viral infections.
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H9-5p, was compared in BPH tissue, cancer tissue, and sur-
rounding noncancerous tissue, and their association with path-
ological outcomes was investigated. 
MATERIALS AND METHODS
Cases and Controls
For this study, a total of 175 samples from noncancerous BPH 
tissues, 50 samples from noncancerous surrounding tissues, 
and 248 samples from cancerous tissues were obtained from 
patients with CaP and BPH at Chungbuk National University 
Hospital (Table 1). A schematic of the study design, which in-
cluded three different cohorts, is shown in Fig. 1. All tissues 
were harvested from patients with CaP who underwent radical 
prostatectomy or palliative transurethral resection (TUR), or 
patients with BPH who underwent TUR. Tissue samples were 
macrodissected within 15 minutes of surgical resection. Each 
prostate specimen was confirmed by analysis of fresh-frozen 
sections, and the remaining tissue was frozen in liquid nitrogen 
and stored at −80°C until use. BPH controls with serum PSA 
levels ≥3 ng/mL underwent transrectal prostate biopsy prior to 
TUR to rule out the presence of cancer. Patients receiving neo-
adjuvant therapies, such as androgen deprivation or radiation 
Table 1. Clinical characteristics of the patients and controls
Characteristic
BPH and prostate cancer tissues BPH, surrounding noncancerous, and prostate cancer tissues Direct staining
Control Case Control Case Control Case
No. 131 192 37 41 7 24
Age (yr) 71.5 (46–89) 69.1 (50–92) 71.6 (58–34) 69.2 (58–80) 73.6 (68–80) 68.9 (65–73)
PSA (ng/mL) 4.9±9.4 143.0±584.5 4.3±4.9 14.9±15.9 11.7±9.0 37.3±87.2
Operation (%)
TURP 131 (100) 57 (29.7) 37 (100) - 7 (100) -
Radical prostatectomy - 135 (70.3) - 41 (100) - 24 (100)
Gleason score (%)
≤6 - 7 (3.6) - 6 (14.6) - 0 (0)
7 - 96 (50.0) - 24 (58.5) - 15 (62.5)
8 - 34 (17.7) - 7 (17.0) - 3 (12.5)
9 - 49 (25.5) - 3 (7.3) - 6 (25)
10 - 6 (3.1) - 1 (2.4) - 0 (0)
TNM stage
T3 or less 126 (65.6) 41 (100) 21 (87.5)
T4 or metastatic 66 (34.4) - 3 (12.5)
Values are presented as median (range), mean±standard deviation, or number (%).
BPH, benign prostatic hyperplasia; PSA, prostate-specific antigen; TURP, transurethral resection of the prostate.
Tissue cohort 192 CaP patients
131 BPH controls
41 CaP patients
37 BPH controls
15 CaP tissues
9 Noncancerous tissues
7 BPH tissues
BPH, cancer and surrounding
noncancerous tissues
Direct staining of miRNAs
Fig. 1. Overview of the study design. Expression of hsv1-miR-
H18 and hsv2-miR-H9-5p was assessed in 192 prostate cancer 
(CaP) tissues and 131 benign prostatic hyperplasia (BPH) non-
cancerous tissues. Then, expression of these microRNAs (miR-
NAs) was compared between matched cancerous and sur-
rounding noncancerous tissues from 41 patients, as well as in 
noncancerous tissues from BPH patients. Lastly, the 2 miRNAs 
were directly stained in cancerous tissues, surrounding noncan-
cerous tissues, and BPH tissues.
therapy, were excluded from the study. Gleason grades were as-
signed to specimens obtained from 12-core transrectal biopsies, 
transurethral resection of the prostate or radical prostatectomy. 
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Tumor stage was estimated from specimens obtained by radical 
prostatectomy, or from computed tomography, magnetic reso-
nance imaging, or bone scans. The collection and analysis of all 
samples was approved by the Institutional Review Board of 
Chungbuk National University, and written informed consent 
was obtained from each subject (approval numbers: 2006-01-
001 and GR2010-12-010). Gleason grades and TNM 2002 stag-
ing were used as prognostic factors.
Purification of miRNA 
Total miRNAs were isolated from 1 mg of each tissue specimen 
using the Genolution miRNA Purification Kit (Genolution 
Pharmaceuticals Inc., Seoul, Korea). Reverse transcription of 
miRNA was conducted with the miScript Reverse Transcrip-
tion Kit (Qiagen Korea, Seoul, Korea) according to the manu-
facturer’s recommended protocol. 
Amplification of miRNA by Real-Time PCR 
To quantify miRNA expression, real-time polymerase chain re-
action (PCR) amplification was performed using a Rotor-Gene 
Q (Qiagen, Valencia, CA, USA) and the miScript PCR Starter 
Kit (Qiagen Korea). Chemically synthesized RNA oligonucle-
otides (Cosmogenetech, Seoul, Korea) corresponding to the 
target miRNAs were used to generate standard curves. The 
standard curves ranged from 30 to 3 ×104 copies. The target 
miRNAs (hsv1-miR-H18 and hsv2-miR-H9-5p) were amplified 
using primers CCCGCCCGCCGGACGCCGGGACC and 
CTCGGAGGTGGAGTCGCGGT, respectively. The conditions 
used for real-time PCR are described in the manufacturer’s pro-
tocol. All samples were tested in triplicate. 
Preparation of QD565/QD525 Nanoparticle-Conjugated hsv1-
miR-H18 and hsv2-miR-H9-Responsive Molecular Beacons  
QD565-hsv1-miR-H18 and QD565-hsv2-miR-H9 beacons specific 
for hsv1-miR-H18 and hsv2-miR-H9 were prepared as previ-
ously described [11]. The sequences of the hsv1-miR-H18 and 
hsv2-miR-H9 beacon and the control scrambled beacon were 
as follows: 5′-NH2-TTCGCTGTGGTCCCGGCGTCCGGCC-
GGG-CGGGCGGGACCACAGCG-BHQ2-3′, 5′-NH2-TC-
GCTGTTCCGCGACTCCACCTCCGTGGCGACAACC-
GTCGGAACAGCG-BHQ2-3′, and 5′-NH2-TTCGCTGTG-
GTCCCGGCGTTTGCCCCCACAGCG-BHQ2-3′, respective-
ly. The carboxyl quantum dote (QD) nanoparticles (Life Tech-
nologies Inc., Eugene, CA, USA) were prepared as previously 
described [12] and then covalently conjugated to the hsv1-miR-
H18 and hsv2-miR-H9 beacons (10 pM) by incubation for 1 
hour at room temperature. N-ethyl-N′-dimethylaminopropyl 
carbodiimide was used to increase the coupling efficiency be-
tween the amine and carboxyl groups. 
Confocal Microscopy of QD565 Particles Within Tissues
Tissues were examined by whole-mount immunocytochemistry 
as previously described [13]. The QD565-hsv1-miR-H18/hsv2-
miR-H9 beacons were used as follows for detection: QD565-
hsv1-miR-H18 beacon and QD525-hsv2-miR-H9 beacons, and 
hsv-miR-HS beacon probes (1:1,000; Bioneer, Daejeon, Korea). 
Excitation was provided by a He/Ne laser (wavelengths, 405 nm 
and 543 nm) and images of selected tissues were visualized us-
ing the 4× and 20× objectives of a scanning Zeiss LSM 710 
confocal microscope (Carl Zeiss, Oberkochen, Germany) with 
an Axiovert 200 M. After scanning specific regions to determine 
the tissue distribution using the region of interest scan feature of 
Zen 2011 software (Carl Zeiss Microimaging GmbH, Jena, Ger-
many), a virtual mask was drawn within the selected tissue area 
for a 5×5 tile scan area. Individual tissues were imaged using a 
5×5 tile scan area with tile scan sections. 
Statistical Analyses
Nonparametric tests were used to compare expression of the 
two miRNAs between groups, because data could not always be 
transformed to achieve normality. Receiver operating charac-
teristic (ROC) curves were used to evaluate the difference in 
expression of the two miRNAs in cancer tissues and BPH con-
trol tissues. Spearman correlation coefficient (r) was used to 
evaluate the correlation between miRNAs in surrounding non-
cancerous tissue with that in matched CaP tissues. Statistical 
analyses was performed using IBM SPSS Statistics ver. 21.0 
(IBM Co., Armonk, NY, USA), and P <0.05 was considered 
statistically significant.
RESULTS
Expression of hsv1-miR-H18 and hsv2-miR-H9-5p in CaP 
To investigate the potential association of two viral hsv1-miR-
H18 and hsv2-miR-H9-5p miRNAs with clinicopathological 
outcomes, the expression of these miRNAs in BPH tissue, can-
cer tissue, and noncancerous surrounding tissues was com-
pared. Real-time PCR results revealed increased expression of 
hsv1-miR-H18 and hsv2-miR-H9-5p in CaP tissue compared 
to that in BPH tissue (each P<0.001) (Fig. 2). To confirm the 
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specificity of the real-time PCR, PCR products were cloned into 
TA cloning vectors, and miRNAs from at least 20 clones were 
sequenced. Results showed 100% identity between the hsv1-
miR-H18 and hsv2-miR-H9-5p clone, while no human homo-
logs were detected in GenBank.  
 To determine whether this analysis might be used as a diag-
nostic tool, an ROC analysis was performed to assess how well 
hsv1-miR-H18 and hsv2-miR-H9-5p expression levels segre-
gate patients with CaP from BPH controls. The areas under the 
ROC for hsv1-miR-H18 and hsv2-miR-H9-5p were 0.914 and 
0.916, respectively, indicating high sensitivity and specificity. 
There was no significant difference in the expression levels of 
the 2 miRNAs and or pathological characteristics between the 
groups, however (i.e., PSA≤10 ng/mL vs. >10 ng/mL; Gleason 
score≤7 vs. ≥8; and ≤T3 vs. T4 or metastasis) (Table 2). This 
indicates these miRNAs may be a useful tool to identify patients 
with CaP, even though their expression levels do not correlate 
with disease severity. 
Expression of hsv1-miR-H18 and hsv2-miR-H9-5p in BPH 
Tissue, CaP Tissue, and Surrounding Noncancerous Tissue 
Both hsv1-miR-H18 and hsv2-miR-H9-5p were found to be 
expressed more highly in CaP tissue and surrounding noncan-
cerous tissue than in BPH tissue (each P<0.001) (Fig. 3). This 
Fig. 2. Expression of hsv1-miR-H18 and hsv2-miR-H9-5p in benign prostatic hyperplasia (BPH) and prostate cancer (CaP) tissues. 
Expression of 2 microRNAs (miRNAs) was markedly higher in CaP tissues than in BPH tissues. The areas under the receiver operat-
ing characteristic (AUC) curves for hsv1-miR-H18 and hsv2-miR-H9-5p were 0.914 and 0.916, respectively.
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indicates that these miRNAs are highly expressed throughout 
the prostate when a tumor is present, and that their expression 
is lower in noncancerous prostate tissues. In addition, miRNA 
expression in surrounding noncancerous tissues significantly 
correlated with that of the matched CaP tissue (Spearman cor-
relation r=0.317 and P=0.044 for hsv1-miR-H18, and r=0.759 
and P<0.001 for hsv2-miR-H9-5p).  
Direct Staining of miRNAs in BPH, CaP, and Noncancerous 
Tissues
A specific QD565-hsv1-miR-H18 and hsv2-miR-H9 beacon de-
tection system was used to stain the two miRNAs in prostate 
Table 2. Expression of hsv1-miR-H18 and hsv2-miR-H9-5p in prostate cancer
Variable No. of patients
hsv1-miR-H18 level 
(×103 copies/miRNA concentration) P-value
hsv2-miR-H9-5p level 
(×103 copies/miRNA concentration) P-value
Age (yr) 0.495 0.412
<70 101 280.4 (58.8–4064.8) 38.3 (14.5–136.8)
≥70 91 293.6 (45.2–2043.7) 31.0 (15.0–114.2)
PSA (ng/mL) 0.465 0.079
<10 78 355.0 (53.5–3913.2) 49.8 (17.6–142.0)
≥10 114 255.5 (45.9–2374.4) 31.1 (12.5–113.7)
Gleason score 0.297 0.195
≤7 103 295.0 (62.8–4685.8) 39.3 (16.3–136.3)
≥8 89 286.1 (38.8–2429.6) 28.1 (12.7–110.4)
Stage 0.198 0.241
T3 or less 126 305.0 (60.0–3290.7) 35.3 (16.8–135.1)
T4 or metastatic 66 257.0 (35.0–1721.1) 30.4 (11.2–104.2)
Values are presented as median (interquartile range).
PSA, prostate-specific antigen.
The Mann-Whitney U-test was used to compare expression levels and clinical variables.
Fig. 3. Correlation between hsv1-miR-H18 and hsv2-miR-H9-5p in benign prostatic hyperplasia (BPH) tissue, prostate cancer (CaP) 
tissue, and matched, surrounding noncancerous tissue. Expression of the 2 microRNAs (miRNAs) was higher in CaP tissue and sur-
rounding noncancerous tissue than in BPH tissue (each comparison, P<0.001); however, there was no significant difference between 
the expression levels in surrounding noncancerous tissue and CaP tissue (each comparison, P>0.05).
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tissue samples (Fig. 4). There was an increase in fluorescence in 
both CaP and surrounding noncancerous tissues compared to 
that in BPH tissues (P<0.05 for hsv1-miR-H18 and hsv2-miR-
H9), confirming the findings from the real-time PCR analysis. 
Further, the staining patterns of the two herpes-encoded miR-
NAs were quite similar, with strong cytoplasmic staining and 
Fig. 4. (A) Direct staining of miRNAs in benign prostatic hyperplasia (BPH) tissues, (B) noncancerous surrounding tissues, and (C) 
cancerous tissues using a QD565-hsv1-miR-H18 and QD565-hsv2-miR-H9 specific beacon detection system. (D) Fluorescence 
emission of the 2 microRNAs (miRNAs) was higher in prostate cancer tissue and the surrounding noncancerous tissue than in BPH 
tissue. Staining for the miRNAs was observed in the cytoplasm of cancer cells and in the cells of the surrounding noncancerous tissue, 
with the epithelial layer staining more strongly than the stroma. Luminal cells, which have direct contact with seminal fluid, showed 
the strongest staining.
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increased staining in the epithelial layer compared to that in the 
stroma. Interestingly, luminal cells, which have direct contact 
with seminal fluid, showed the strongest fluorescence intensity. 
DISCUSSION
Here, we show that the expression levels of hsv1-miR-H18 and 
hsv2-miR-H95p were higher in CaP and surrounding noncan-
cerous tissue than in BPH tissues. This suggests that these 2 
miRNAs may be specific biomarkers for tumor-containing or-
gans, as opposed to cancer-specific markers. These findings 
may be clinically important, suggesting it may be possible to 
detect early tumorigenesis before the cancerous tissue compris-
es a large portion of the prostate. The ability to diagnosis cancer 
while the disease is still localized within the originating organ 
has important implications, including increased likelihood of 
curative resection. Numerous previous studies have focused on 
the identification of cancer-specific biomarkers for CaP; how-
ever, when the disease is localized, the sensitivity and specificity 
of biomarker detection in body fluids is very low. PSA is a pros-
tate-specific marker that can be detected in patient serum, and 
although it is considered an outstanding marker for detecting 
CaP, it is not a cancer-specific marker, and so patients are often 
subjected to the painful transrectal biopsy procedure in order to 
rule out cancer. In this study, we evaluated two herpes virus-en-
coded miRNAs as organ-specific markers of cancer. We found 
that the expression levels of hsv1-miR-H18 and hsv2-miR-H9-
5p were significantly higher in CaP tissue and the surrounding 
noncancerous tissue than in BPH tissue (each comparison, 
P<0.001). Further, these results may explain why the miRNAs 
were easily detected in urine samples of patients with CaP [10]. 
 Since the discovery of viral miRNAs in human tissues [14], 
many researchers have focused on identifying the functions 
and roles of these molecules in human cells; however, such re-
search is still in its initial stages. While certain viral miRNAs are 
thought to enable viruses to evade the host immune system [8], 
to our knowledge, the direct relationship between virus-encod-
ed miRNAs and initiation, progression, and metastasis of CaP 
has not been studied. Recent evidence suggests that CaP is as-
sociated with infection and inflammation caused by bacteria 
and viruses [3-5]. Therefore, it is possible that hsv1-miR-H18 
and hsv2-miR-H9-5p play a role in CaP carcinogenesis, a find-
ing that would be supported by our real-time PCR results. Fu-
ture studies will be required to address this possibility.
 One of the major risk factors for CaP is sexually transmitted 
infections (STIs). Given the solid evidence that human papillo-
mavirus is the major causative agent of cervical cancer [15], it 
has been hypothesized that STIs such as those caused by Neisse-
ria gonorrhoeae, Treponema pallidum, Chlamydia trachomatis, 
Trichomonas vaginalis, and herpes viruses may be associated 
with carcinogenesis of the prostate. While bacterial infections 
are also thought to cause inflammation and atrophy of the pros-
tate, viral infections, and herpes viruses in particular, can lead to 
the transformation of prostate epithelial cells [16]. Several epi-
demiologic studies have suggested possible associations be-
tween STIs and CaP [17-19], but the data are inconsistent. A re-
cent meta-analysis suggested that herpes virus type 2 infection 
is associated with an increased risk of CaP (odds ratio, 1.209; 
95% confidence interval [CI], 1.003–1.456) [20]. However, an-
other meta-analysis showed that men who reported never hav-
ing had an STI were at increased risk for CaP (summary relative 
risk [SRR], 1.49; 95% CI, 1.19–1.92), and that men with gonor-
rheal infection also showed an increased risk of CaP (SRR, 1.20; 
95% CI, 1.05–1.37) [6]. However, no single STI, including her-
pes virus, has been definitively linked to CaP [6]. These conflict-
ing findings may be a result of different methods used to detect 
antibodies against STI-causing agents in serum. Therefore, fur-
ther well-designed investigations are needed to elucidate the 
potential links between STIs and increased risk of CaP.
 Because the prostate is not a target organ for herpes virus 
replication, it is possible that the presence of herpes virus-en-
coded miRNAs in CaP tissues and urine might not be linked to 
herpes infection of the prostate. However, given that there are 
no human homologs of either hsv1-miR-H18 or hsv2-miR-H9-
5p, and that other herpes-encoded miRNAs (e.g., hsv1-miR-
H13, hsv2-miR-H2, and hsv2-miR-H7) are also enriched in 
CaP tissues (data not shown), it is difficult to rule out a direct 
association between herpes infection, with the subsequent pres-
ence of virus-encoded miRNAs, and CaP development. There-
fore, the findings presented herein may provide the missing 
link between herpes virus infection and carcinogenesis of the 
prostate, and support the theory that STIs are a major risk fac-
tor for CaP. 
 Our study had several inherent weaknesses. First, anatomical 
differences in the expression of the 2 virus-encoded miRNAs 
were not considered, even though BPH originates from the 
transitional zone, while CaP is usually from the peripheral 
zone. Second, we did not find any direct evidence of the source 
of these virus-encoded miRNAs. Further studies are needed to 
investigate the origin of these miRNAs. Lastly, because we did 
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not perform an in vitro experiment, the influence of these miR-
NAs on CaP cells is uncertain. 
 In conclusion, there is increased expression of hsv1-miR-
H18 and hsv2-miR-H95p in CaP and surrounding noncancer-
ous tissues compared to that in BPH tissues, suggesting that 
herpes virus-encoded miRNAs might be associated with tu-
morigenesis in the prostate. Further investigation will be re-
quired in order to elucidate the role of these miRNAs in relation 
to herpes viral infection as well as CaP, and to confirm their va-
lidity as biomarkers. 
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